ADA evidence-grading system for “Standards of Medical Care in Diabetes”
Level of evidence . | Description . |
---|---|
A | Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered, including |
• Evidence from a well-conducted multicenter trial | |
• Evidence from a meta-analysis that incorporated quality ratings in the analysis | |
Compelling nonexperimental evidence, i.e., “all or none” rule developed by the Centre for Evidence-Based Medicine at the University of Oxford | |
Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including | |
• Evidence from a well-conducted trial at one or more institutions | |
• Evidence from a meta-analysis that incorporated quality ratings in the analysis | |
B | Supportive evidence from well-conducted cohort studies |
• Evidence from a well-conducted prospective cohort study or registry | |
• Evidence from a well-conducted meta-analysis of cohort studies | |
Supportive evidence from a well-conducted case-control study | |
C | Supportive evidence from poorly controlled or uncontrolled studies |
• Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results | |
• Evidence from observational studies with high potential for bias (such as case series with comparison with historical controls) | |
• Evidence from case series or case reports | |
Conflicting evidence with the weight of evidence supporting the recommendation | |
E | Expert consensus or clinical experience |
Level of evidence . | Description . |
---|---|
A | Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered, including |
• Evidence from a well-conducted multicenter trial | |
• Evidence from a meta-analysis that incorporated quality ratings in the analysis | |
Compelling nonexperimental evidence, i.e., “all or none” rule developed by the Centre for Evidence-Based Medicine at the University of Oxford | |
Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including | |
• Evidence from a well-conducted trial at one or more institutions | |
• Evidence from a meta-analysis that incorporated quality ratings in the analysis | |
B | Supportive evidence from well-conducted cohort studies |
• Evidence from a well-conducted prospective cohort study or registry | |
• Evidence from a well-conducted meta-analysis of cohort studies | |
Supportive evidence from a well-conducted case-control study | |
C | Supportive evidence from poorly controlled or uncontrolled studies |
• Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results | |
• Evidence from observational studies with high potential for bias (such as case series with comparison with historical controls) | |
• Evidence from case series or case reports | |
Conflicting evidence with the weight of evidence supporting the recommendation | |
E | Expert consensus or clinical experience |